Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Addy

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of Clinical Psychopharmacology|June 23, 2012
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug usersKerri A Schoedel, Carol Addy, Bijan Chakraborty, et al.
Advances in Therapy|November 8, 2008
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarinJules I Schwartz, Stephanie Dunbar, Jinyu Yuan, et al.
Clinical Therapeutics|February 13, 2016
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes MellitusCarol Addy, Daniel Tatosian, Xiaoli S Glasgow, et al.
The AAPS Journal|February 10, 2009
Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse eventMark Stroh, Carol Addy, Yunhui Wu, et al.
Cell Metabolism|August 3, 2017
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench InvestigationChai-Wan Kim, Carol Addy, Jun Kusunoki, et al.
Journal of Pediatric Gastroenterology and Nutrition|April 21, 2023
An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic SteatohepatitisNidhi P Goyal, Ali Mencin, Kimberly P Newton, et al.
Journal of Clinical Pharmacology|February 9, 2008
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteersCarol Addy, Susie Li, Nancy Agrawal, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 21, 2010
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humansBindhu Karanam, Carol Addy, Thomas Bateman, et al.
Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.
Journal of Clinical Pharmacology|May 27, 2016
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy SubjectsRajesh Krishna, Carol Addy, Daniel Tatosian, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of Clinical Psychopharmacology|June 23, 2012
Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug usersKerri A Schoedel, Carol Addy, Bijan Chakraborty, et al.
Advances in Therapy|November 8, 2008
Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarinJules I Schwartz, Stephanie Dunbar, Jinyu Yuan, et al.
Clinical Therapeutics|February 13, 2016
Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes MellitusCarol Addy, Daniel Tatosian, Xiaoli S Glasgow, et al.
The AAPS Journal|February 10, 2009
Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse eventMark Stroh, Carol Addy, Yunhui Wu, et al.
Cell Metabolism|August 3, 2017
Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench InvestigationChai-Wan Kim, Carol Addy, Jun Kusunoki, et al.
Journal of Pediatric Gastroenterology and Nutrition|April 21, 2023
An Open Label, Randomized, Multicenter Study of Elafibranor in Children With Nonalcoholic SteatohepatitisNidhi P Goyal, Ali Mencin, Kimberly P Newton, et al.
Journal of Clinical Pharmacology|February 9, 2008
Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteersCarol Addy, Susie Li, Nancy Agrawal, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|August 21, 2010
Metabolism and excretion of [14C]taranabant, a cannabinoid-1 inverse agonist, in humansBindhu Karanam, Carol Addy, Thomas Bateman, et al.
Journal of Clinical Pharmacology|June 4, 2009
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's diseaseCarol Addy, Chris Assaid, David Hreniuk, et al.
Journal of Clinical Pharmacology|May 27, 2016
Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy SubjectsRajesh Krishna, Carol Addy, Daniel Tatosian, et al.
Pageof 3